Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 6.30 is 7444% above its 5-year average of 0.08, near the high end of its 5-year range (-11.20–6.30).
As of the fiscal period ended Tuesday, June 30, 2026. 222.21% above its 12-month average of 1.96.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 6.30.
DEBT TO EQUITY RATIO
6.30
DEBT TO EQUITY RATIO AVG TTM
1.96
DEBT TO EQUITY RATIO AVG 3Y
-0.05
DEBT TO EQUITY RATIO AVG 5Y
0.08
DEBT TO EQUITY RATIO AVG 10Y
0.06
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+222.21%
CURRENT VS 3Y AVG
+12575.58%
CURRENT VS 5Y AVG
+7444.32%
CURRENT VS 10Y AVG
+9927.08%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 774 covered companies
CURRENT VS SECTOR MEDIAN
+5629.64%
vs the sector median at left
Allarity Therapeutics, Inc.
Market Cap
$15.68M
Debt to Equity Ratio
6.30
TTM Avg
1.96
3Y Avg
-0.05
5Y Avg
0.08
Market Cap
$15.58M
Debt to Equity Ratio
0.68
TTM Avg
0.52
3Y Avg
0.30
5Y Avg
0.24
Market Cap
$15.30M
Debt to Equity Ratio
1.28
TTM Avg
0.21
3Y Avg
0.13
5Y Avg
0.09
Market Cap
$14.94M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$16.52M
Debt to Equity Ratio
N/A
TTM Avg
3.08
3Y Avg
1.54
5Y Avg
1.03
Market Cap
$14.73M
Debt to Equity Ratio
N/A
TTM Avg
2.55
3Y Avg
1.42
5Y Avg
0.94
Market Cap
$16.64M
Debt to Equity Ratio
0.21
TTM Avg
0.47
3Y Avg
0.45
5Y Avg
0.39
Market Cap
$16.74M
Debt to Equity Ratio
0.03
TTM Avg
0.03
3Y Avg
0.03
5Y Avg
0.04
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Allarity Therapeutics, Inc. (ALLR) | $15.68M | 6.30 | 1.96 | -0.05 | 0.08 |
| Jin Medical International Ltd. (ZJYL)vs › | $15.58M | 0.68 | 0.52 | 0.30 | 0.24 |
| BioCardia, Inc. (BCDA)vs › | $15.78M | 0.11 | 0.86 | 0.69 | 0.45 |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.30M | 1.28 | 0.21 | 0.13 | 0.09 |
| Pasithea Therapeutics Corp. (KTTA)vs › | $14.94M | 0.00 | 0.00 | 0.00 | 0.00 |
| Dyadic International, Inc. (DYAI)vs › | $16.52M | N/A | 3.08 | 1.54 | 1.03 |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $14.73M | N/A | 2.55 | 1.42 | 0.94 |
| Bionano Genomics, Inc. (BNGO)vs › | $16.64M | 0.21 | 0.47 | 0.45 | 0.39 |
| Palatin Technologies, Inc. (PTN)vs › | $16.74M | 0.03 | 0.03 | 0.03 | 0.04 |
| TScan Therapeutics, Inc. (TCRX)vs › | $16.82M | 1.32 | 0.58 | 0.66 | 0.53 |
Debt/Equity
6.30
Current Ratio
1.11
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 6.30 |
| 2026-03-31 | 3.11 |
| 2025-12-31 | 0.14 |
| 2025-09-30 | 0.12 |
| 2025-06-30 | 0.11 |
| 2025-03-31 | 0.07 |
| 2024-12-31 | 0.11 |
| 2024-09-30 | 0.10 |
| 2024-06-30 | 0.07 |
| 2024-03-31 | -0.42 |
| 2023-12-31 | -0.47 |
| 2023-09-30 | -0.35 |
| 2023-06-30 | -2.06 |
| 2023-03-31 | -11.20 |
| 2022-12-31 | 1.98 |
| 2022-09-30 | 0.31 |
| 2022-06-30 | 0.11 |
| 2022-03-31 | 0.06 |
| 2021-12-31 | 0.06 |
| 2021-09-30 | 0.04 |
| 2021-06-30 | 0.01 |
| 2021-03-31 | 0.09 |
| 2020-12-31 | 0.11 |
| 2020-09-30 | 0.02 |
| 2020-06-30 | 0.05 |
| 2020-03-31 | 0.02 |
| 2019-12-31 | 0.05 |
| 2019-09-30 | 0.29 |
| 2019-06-30 | 0.16 |
| 2019-03-31 | 0.27 |
| 2018-12-31 | 0.12 |
| 2018-09-30 | 0.05 |
| 2018-06-30 | 0.00 |
| 2018-03-31 | 0.00 |
| 2017-12-31 | 0.00 |
| 2017-09-30 | 0.00 |
| 2017-06-30 | 0.00 |
| 2017-03-31 | 0.00 |
| 2016-12-31 | 0.00 |
| 2016-09-30 | 0.00 |
| 2016-06-30 | 0.00 |
| 2016-03-31 | 0.00 |
| 2015-12-31 | 0.00 |
| 2015-09-30 | 0.00 |
| 2015-06-30 | 0.00 |
| 2015-03-31 | 0.00 |
